As cell and gene therapies from leaders like Bristol Myers Squibb, bluebird bio, and Orchard Therapeutics transform healthcare, the need for strong medical affairs leadership has never been greater. At this summit, you’ll gain insights from the brightest minds in the industry on how medical affairs is driving successful launches and advancing these new therapies.

The Cell & Gene Therapy Medical Affairs Summit demonstrates how medical affairs teams can better communicate, collaborate, and connect with healthcare providers, key opinion leaders, and payors. Through interactive workshops and sessions addressing today’s pressing challenges, you'll gain invaluable knowledge on improving both internal and external communications, accelerating therapies to market, and ensuring successful launches.

Whether you’re preparing for an IND submission or navigating post-launch engagement, this summit is a chance gain end-to-end experience from leaders who have been there, like Adaptimmune, Caribou Biosciences, Editas Medicine, and more. Take part in discussions on new indications like solid tumors and Parkinson’s, and discover how to break new ground in these areas.